Iris Acquisition is a globally focused SPAC franchise dedicated to identifying and partnering with high-quality companies positioned to unlock accelerated growth through a public market listing. The platform is backed by an experienced management team with deep pedigree across private equity and investment banking, spanning multiple sectors, and long-standing relationships across the global SPAC ecosystem.
Iris launched its inaugural $276 million SPAC and listed on Nasdaq. That vehicle successfully completed a business combination in 2025 with Liminatus Pharma, Inc., a clinical-stage life sciences company focused on the development of novel oncology therapies and raised a $15 million PIPE.
Building on this track record, Iris launched its second SPAC in 2026, raising $168 million and listing on the NYSE, with a 24-month timeframe to complete a business combination.